ABSTRACT
Background
Leadless pacemaker implantation traditionally relies on fluoroscopy and contrast‐guided techniques. However, in patients with advanced chronic kidney disease, the use of contrast carries a risk of nephrotoxicity, and fluoroscopy leads to additional ionizing radiation exposure.
Case Summary
We report a case of a 69‐year‐old man with occasional sinus arrest and end‐stage renal disease on hemodialysis who successfully underwent implantation of an Aveir VR leadless pacemaker (Abbott, USA) entirely under transthoracic echocardiographic (TTE) guidance, without fluoroscopy or contrast. Using a Philips EPIQ system with an X5‐1 transducer, key procedural steps—including navigation, septal positioning, pacing threshold testing, and final deployment—were completed under real‐time ultrasound visualization. Post‐procedural pacing parameters were optimal, and no complications occurred. Chest radiography confirmed appropriate device position.
Conclusion
This case demonstrates the potential feasibility and safety of an ultrasound‐guided implantation technique for the Aveir VR leadless pacemaker. It may offer a promising alternative for patients with contraindications to radiation or contrast agents. Larger studies are needed to validate and standardize this approach.
1. Case Description
A 69‐year‐old man was referred to our hospital for permanent pacemaker implantation due to sick sinus syndrome with the longest sinus arrest lasting for more than 10 s. The 12‐lead ECG showed sinus bradycardia at 58 bpm, with a narrow QRS duration of 102 ms and normal AV conduction. Sleep monitoring and thyroid function testing were performed, and secondary causes of bradycardia were excluded. He had end‐stage renal disease and was receiving maintenance hemodialysis. Because conventional transvenous pacemakers may increase the risk of infection, a leadless Aveir VR device (Abbott, USA) was selected to avoid lead‐ and pocket‐related complications. To prevent further renal injury and eliminate radiation exposure, the procedure was performed entirely under transthoracic echocardiographic (TTE) guidance, without fluoroscopy or contrast media, using a Philips EPIQ system with an X5‐1 transducer.
After femoral venous access was obtained, an echogenic stiff guidewire (Panna wire) within an MP catheter was advanced to the inferior vena cava‐right atrium (IVC‐RA) junction under TTE guidance (Figure 1A). The MP catheter was removed, and a 27F introducer was inserted along the Panna wire into the RA (Figure 1B). The Aveir VR delivery system was advanced through the introducer to IVC‐RA. The introducer and protective sleeve were pulled back to expose the device, allowing blood contact and communication with the external programmer for device activation. Under TTE, the delivery system was clearly visualized at the site of the IVC‐RA junction (Figure 1C). After resetting the sleeve, the delivery system was manipulated across the tricuspid annulus into the right ventricle (RV) from the apical four‐chamber view (Figure 1D). The delivery system was advanced and placed at the RV septum near the apex (Figure 1E). After excluding positioning at the RV outflow tract or free wall via multiple echocardiographic views, the device was confirmed at the septum position. The protective sleeve was retracted under TTE monitoring, and the device was visualized locating at the septum. Initial mapping measurements showed impedance of 330 Ω, sensing amplitude of 9.7 mV, and capture threshold of 0.75 V at 0.4 ms. The helix of the device was then slowly screwed into the septum, guided by the number of button clicks. Because the ‘V’ orientation marker could not be visualized on ultrasound, fixation depth was judged using the known range of 14–16 button clicks (≈1.5 rotations). Impedance and current of injury were monitored at 4, 8, 10, 12, and 14 clicks (Figure 2). Stable fixation was achieved at 15 clicks, allowing entry into tether mode. After subsequent deflection testing, pacing parameters remained stable (Table 1). After confirming the position of the device near the septum without repositioning, the device was released and the delivery system was pulled back into the IVC. Both TTE and chest radiography confirmed a stable device position at the low RV septum near the apex (Figure 1F). The last procedural measurements showed impedance of 660 Ω, sensing amplitude of 11.4 mV, and capture threshold of 0.5 V at 0.4 ms. The follow‐up at 6 months showed a slightly elevated threshold of 1.25 V at 0.4 ms, with an impedance of 720 Ω, a sensing amplitude of 12.5 mV, and an estimated battery life of 17.5 years at a 30% ventricular pacing percentage.
FIGURE 1.

Leadless pacemaker implantation under transthoracic echocardiographic guidance. A: The panna wire reached the IVC‐RA junction; B: The 27F introducer was advanced over the panna wire to the IVC‐RA junction; C: The Aveir delivery system was exposed to the blood flow and connected to the programmer; D: The delivery catheter crossed the tricuspid valve, visualized in the apical four‐chamber view under ultrasound guidance; E: The helix tip reached the interventricular septum; F: A final chest X‐ray confirmed the position of the leadless pacemaker. [Colour figure can be viewed at wileyonlinelibrary.com]
FIGURE 2.

The dynamic changes of injury current during the procedure.
TABLE 1.
Real‐time monitoring of pacing parameters during the procedure.
| Steps | Impedance, Ω | Sensing, mV | Threshold, V/0.4ms |
|---|---|---|---|
| Mapping | 330 | 9.7 | 0.75 |
| 4 Clicks | 380 | — | — |
| 8 Clicks | 370 | — | — |
| 10 Clicks | 450 | — | — |
| 12 Clicks | 580 | — | — |
| 14 Clicks | 670 | — | — |
| 15 Clicks | 910 | 10.7 | 1.0 |
| Deflection test | 620 | 9.2 | 1.0 |
| After deployment | 630 | 9.9 | 0.5 |
This case demonstrates that TTE‐guided implantation may be a feasible approach for Aveir VR deployment. Compared with the Micra system, active fixation with a helix tip allows more precise device positioning and may reduce procedure‐related complications under TTE guidance. The soft protective sleeve and pre‐fixation mapping also facilitate optimal site selection. Larger studies are needed to establish standardized procedural steps of this novel technique. This approach offers an alternative option for patients who cannot receive contrast or X‐ray and may enable Aveir VR implantation in catheter labs without fluoroscopy.
Conflicts of Interest
The authors declare no conflicts of interest.
Contributor Information
Xiaohan Fan, Email: fanxiaohan@fuwaihospital.org.
Xiangbin Pan, Email: panxiangbin@fuwaihospital.org.
